Form 4: Director Stock Grant at Recursion Pharmaceuticals

Dean Y. Li, a Director at Recursion Pharmaceuticals, received a stock grant of 3,747 shares of Class A Common Stock on July 1, 2026.

Summary

• Dean Y. Li, a Director at Recursion Pharmaceuticals, Inc. (RXRX), was granted 3,747 shares of Class A Common Stock on July 1, 2026.
• This grant was made under the company's Outside Director Compensation Policy.
• Following this transaction, Mr. Li beneficially owns 1,473,329 shares of Class A Common Stock.
• These shares are held directly and indirectly through the Dean Y. Li Revocable Trust (1,422,048 shares) and the Dean Y. Li 2021 Family Trust (421,000 shares).

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents a standard director compensation event rather than a significant financial or strategic development.

Positives

• Director compensation in the form of stock aligns management interests with shareholders.
• The grant of 3,747 shares indicates continued investment and commitment from a key director.
• Mr. Li's substantial beneficial ownership (1,473,329 shares) suggests significant alignment with shareholder value.

Future Outlook

No specific future outlook or guidance is provided in this filing, as it pertains to a director's stock grant.

Industry Context

StockSavvy.ai notes that director stock grants are a common practice in the biotechnology and pharmaceutical sectors, aiming to attract and retain experienced board members by aligning their financial interests with the company's long-term performance and shareholder value.

Stakeholder Impact

• Shareholders: The stock grant aligns director interests with shareholder value, potentially leading to better governance and strategic decisions.
• Employees: Standard director compensation practices can contribute to overall company stability and attractiveness as an employer.
• Management: Reinforces the compensation structure for directors, ensuring alignment with company performance.

Key Dates

Keywords

Recursion Pharmaceuticals, RXRX, Form 4, Director Compensation, Stock Grant, Class A Common Stock, Beneficial Ownership, Dean Y. Li